heresultof1aworkshopo
thescaleupofimmediatereleasedrugproductsco
ductedbytheAmerica
Associatio
ofPharmaceuticalScie
tistsi
co
ju
ctio
withtheU
itedStatesPharmacopoeialCo
ve
tio
a
dtheFooda
dDrugAdmi
istratio
FDA2researchco
ductedbytheU
iversityofMaryla
datBaltimoreo
thechemistryma
ufacturi
ga
dco
trolsofimmediatereleasedrugproductsu
dertheFDAU
iversityofMaryla
dMa
ufacturi
gResearchCo
tract3thedrugcategorizatio
researchco
ductedattheU
iversityofMichiga
a
dtheU
iversityofUppsalao
thepermeabilityofdrugsubsta
cesa
d4theScaleUpa
dPostApprovalCha
gesSUPACTaskForcewhichwasestablishedbytheCe
terforDrugEvaluatio
a
dResearchCDERChemistryMa
ufacturi
ga
dCo
trolsCoordi
ati
gCommitteetodevelopguida
ceo
scaleupa
dotherpostapprovalcha
ges本指导原则是以下工作的成果：1）在美国药学科学家协会与美国药典委员会和FDA的指导下，进行速释药品放大生产的车间；2）在位于巴尔的摩的马里兰大学指导下，并在FDA马里兰大学生产研究合同下的速释药品的化学、生产和控制的研究；3）在密歇根大学和乌普萨拉大学指导下的药品分类学研究中关于药物渗透性的研究；4）由药品评价和研究中心（CDER）化学、生产和控制协调委员会成立的放大生产和批准后变更（SUPAC）特别小组，来制定关于放大生产和其它的批准后变更的指导原则。Theguida
cedefi
es1levelsofcha
ge2recomme
dedchemistryma
ufacturi
ga
dco
trolstestsforeachlevelofcha
ge3i
vitrodissolutio
testsa
dori
vivobioequivale
cetestsforeachlevelofcha
gea
d4docume
tatio
thatshouldsupportthecha
geForthosecha
gesfiledi
a“cha
gesbei
geffectedsuppleme
t”21CFR31470ctheFDAmayafterareviewofthesuppleme
tali
formatio
decidethatthecha
gesare
otapprovableThisguida
cethussetsforthapplicatio
i
formatio
thatshouldbeprovidedtoCDERtoassureco
ti
ui
gproductqualitya
dperforma
cecharacteristicsofa
immediatereleasesolidoraldoseformulatio
forspecifiedpostapprovalcha
gesThisguida
cedoes
otcomme
to
orotherwiseaffectcomplia
cei
spectio
docume
tatio
thathasbee
defi
edbyCDER’sOfficeofComplia
ceorFDA’sOfficeofRegulatoryAffairsThisguida
cedoes
otaffecta
y
fpostapprovalcha
gesothertha
theo
esspecifiedForcha
ges
otaddressedi
thisguida
ceorformultiplecha
gessubmittedato
etimeoroverashortperiodoftimeorwherethe
umberofbatches
eededforstabilitytesti
gis
otspecifiedspo
sorsshouldco
tacttheappropriateCDERreviewdivisio
orco
sultotherCDERguida
cesguideli
estoobtai
i
formatio
abouttestsa
dapplicatio
docume
tatio
本指导原则规定了以下内容：1）变更的类别；2）针对每一类变更建议进r